Fundamental Analysis of PROVENTION BIO INC(NASDAQ:PRVB) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PRVB. PRVB was compared to 198 industry peers in the Pharmaceuticals industry. PRVB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PRVB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRVB has reported negative net income.

PRVB had a negative operating cash flow in the past year.

In the past 5 years PRVB always reported negative net income.

PRVB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for PRVB are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 96.03%, PRVB belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.

PRVB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.03%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRVB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PRVB has more shares outstanding

Compared to 5 years ago, PRVB has more shares outstanding

The debt/assets ratio for PRVB is higher compared to a year ago.

2.2 Solvency

An Altman-Z score of 8.65 indicates that PRVB is not in any danger for bankruptcy at the moment.

PRVB has a Altman-Z score of 8.65. This is amongst the best in the industry. PRVB outperforms 87.61% of its industry peers.

PRVB has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.

PRVB's Debt to Equity ratio of 0.19 is in line compared to the rest of the industry. PRVB outperforms 43.58% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF	N/A
Altman-Z	8.65

ROIC/WACCN/A

WACC8.84%

2.3 Liquidity

PRVB has a Current Ratio of 1.93. This is a normal value and indicates that PRVB is financially healthy and should not expect problems in meeting its short term obligations.

PRVB has a Current ratio of 1.93. This is in the lower half of the industry: PRVB underperforms 65.60% of its industry peers.

A Quick Ratio of 1.92 indicates that PRVB should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.92, PRVB is not doing good in the industry: 61.47% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.93
Quick Ratio	1.92

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PRVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.09%, which is quite good.

Looking at the last year, PRVB shows a very strong growth in Revenue. The Revenue has grown by 824.37%.

EPS 1Y (TTM)12.09%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-9.76%

Revenue 1Y (TTM)824.37%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q1408.09%

3.2 Future

PRVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.69% yearly.

PRVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.71% yearly.

EPS Next Y-18.96%

EPS Next 2Y27.12%

EPS Next 3Y36.47%

EPS Next 5Y40.69%

Revenue Next Year372.61%

Revenue Next 2Y275.03%

Revenue Next 3Y253.14%

Revenue Next 5Y138.71%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PRVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PRVB's earnings are expected to grow with 36.47% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y27.12%

EPS Next 3Y36.47%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PRVB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROVENTION BIO INC

NASDAQ:PRVB (4/26/2023, 7:02:36 PM)

After market: 25 +0.02 (+0.08%)

24.98

+0.75 (+3.1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.37B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	96.03%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.19
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.93
Quick Ratio	1.92
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)12.09%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-18.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)824.37%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROVENTION BIO INC (PRVB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens